China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in Holland-based Xeltis AG, along with an exclusive license for the development, manufacturing, and commercialization of Xeltis’s endogenous tissue repair product aXess in Greater China. The deal, valued at €15 million ($15.2 million), grants Grand Pharma priority rights to negotiate for other indications of the product.
Product and Market Context
aXess is designed to provide a structural framework for autologous tissue repair in hemodialysis patients with end-stage renal disease (ESRD), accelerating dialysis access establishment and reducing thrombosis and complications. The product is currently in first-in-human trials abroad.
China has 580,000 hemodialysis patients, with the number expected to grow at a 15% CAGR over the next five years. Autologous arteriovenous fistula (AVF) is the primary dialysis access method, but over 40% of patients develop AVF stenosis within a year, with the rate increasing over time. aXess aims to offer a safer, more effective blood access solution.-Fineline Info & Tech
